Treosulfan-based conditioning for inborn errors of immunity
- PMID: 34094045
- PMCID: PMC8141989
- DOI: 10.1177/20406207211013985
Treosulfan-based conditioning for inborn errors of immunity
Abstract
Inborn errors of immunity (IEI) are inherited disorders that lead to defects in the development and/or function of the immune system. The number of disorders that can be treated by haematopoietic stem-cell transplantation (HSCT) has increased rapidly with the advent of next-generation sequencing. The methods used to transplant children with IEI have improved dramatically over the last 20 years. The introduction of reduced-toxicity conditioning is an important factor in the improved outcome of HSCT. Treosulfan has myeloablative and immunosuppressive properties, enabling engraftment with less toxicity than traditionally used doses of busulfan. It is firmly incorporated into the conditioning guidelines of the Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation. Unlike busulfan, pharmacokinetically guided dosing of treosulfan is not part of routine practice, but data are emerging which indicate that further improvements in outcome may be possible, particularly in infants who have a decreased clearance of treosulfan. It is likely that individualized dosing, not just of treosulfan, but of all agents used in conditioning regimens, will be developed and implemented in the future. This will lead to a reduction in unwanted variability in drug exposure, leading to more predictable and adjustable exposure, and improved outcome of HSCT, with fewer late adverse effects and improved quality of life. Such conditioning regimens can be used as the basis to study the need for additional agents in certain disorders which are difficult to engraft or require high levels of donor chimerism, the dosing of individual cellular components within grafts, and effects of adjuvant cellular or immunotherapy post-transplant. This review documents the establishment of treosulfan worldwide, as a safe and effective agent for conditioning children with IEI prior to HSCT.
Keywords: haematopoietic stem cell transplantation; inborn errors of immunity; treosulfan.
© The Author(s), 2021.
Conflict of interest statement
Conflict of interest statement: The authors declare that there is no conflict of interest.
Similar articles
-
The impact of Treosulfan-based conditioning for inborn errors of immunity: Is dose monitoring crucial?Clin Transplant. 2023 Sep;37(9):e15083. doi: 10.1111/ctr.15083. Epub 2023 Aug 3. Clin Transplant. 2023. PMID: 37534623
-
Outcome of treosulfan-based reduced-toxicity conditioning regimens for HSCT in high-risk patients with primary immune deficiencies.Pediatr Transplant. 2018 Nov;22(7):e13266. doi: 10.1111/petr.13266. Epub 2018 Jul 11. Pediatr Transplant. 2018. PMID: 29992714
-
European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.Pediatr Blood Cancer. 2016 Jan;63(1):139-48. doi: 10.1002/pbc.25764. Epub 2015 Sep 23. Pediatr Blood Cancer. 2016. PMID: 26398915
-
Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives.Clin Pharmacokinet. 2018 Oct;57(10):1255-1265. doi: 10.1007/s40262-018-0647-4. Clin Pharmacokinet. 2018. PMID: 29557088 Free PMC article. Review.
-
Optimizing treatment efficacy and fertility preservation in patients undergoing hematopoietic stem cell transplantation: A narrative review of ovarian shielding with total-body irradiation or treosulfan-based conditioning regimens.Reprod Med Biol. 2025 Apr 17;24(1):e12648. doi: 10.1002/rmb2.12648. eCollection 2025 Jan-Dec. Reprod Med Biol. 2025. PMID: 40255903 Free PMC article. Review.
Cited by
-
Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial.Bone Marrow Transplant. 2024 Jan;59(1):107-116. doi: 10.1038/s41409-023-02135-9. Epub 2023 Nov 4. Bone Marrow Transplant. 2024. PMID: 37925531 Free PMC article. Clinical Trial.
-
Personalized hematopoietic stem cell transplantation for inborn errors of immunity.Front Immunol. 2023 Apr 5;14:1162605. doi: 10.3389/fimmu.2023.1162605. eCollection 2023. Front Immunol. 2023. PMID: 37090739 Free PMC article. Review.
References
-
- Fischer A, Notarangelo LD, Neven B, et al.. Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers 2015; 1: 15061. - PubMed
-
- Gatti RA, Meuwissen HJ, Allen HD, et al.. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968; 2: 1366–1369. - PubMed
-
- De Koning J, Van Bekkum DW, Dicke KA, et al.. Transplantation of bone-marrow cells and fetal thymus in an infant with lymphopenic immunological deficiency. Lancet 1969; 293: 1223–1227. - PubMed
-
- Bach FH, Albertini RJ, Joo P, et al.. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968; 2: 1364–1366. - PubMed
Publication types
LinkOut - more resources
Full Text Sources